Trial Profile

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Afatinib (Primary) ; Atezolizumab (Primary) ; Cetuximab (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary) ; Gemcitabine (Primary) ; Ipilimumab (Primary) ; Larotrectinib (Primary) ; Niraparib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Regorafenib (Primary) ; Sunitinib (Primary) ; Talazoparib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary) ; Vemurafenib (Primary)
Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; B-cell lymphoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Uterine cancer
Focus Therapeutic Use
Acronyms TAPUR

30 Apr 2025 Results(n=29) cohort of pts with solid tumors with ATM mutation (mut) or deletion (del) treated with Tala are presented at the 116th Annual Meeting of the American Association for Cancer Research
30 Apr 2025 Results(n=28) in a cohort of pts with solid tumors with FGFR2 alterations treated with S (Sunitinib) were presented at the 116th Annual Meeting of the American Association for Cancer Research
25 Apr 2025 Planned number of patients changed from 3791 to 4200.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com